Opinion

Opinion

Court
District Court, E.D. Pennsylvania
Filed
May 29, 2026
Cited by
0 cases
Authority
More cited than 41.3%

The opinion

IN THE UNITED STATES DISTRICT COURT

FOR THE EASTERN DISTRICT OF PENNSYLVANIA

DE LAGE LANDEN FINANCIAL :

SERVICES, INC., :

:

Plaintiff, :

:

v. : CIVIL ACTION

:

SOUTHERN ILLINOIS INTERNAL :

MEDICINE, LTD; AND MAZHAR H. : NO. 25-1619

LAKHO, :

:

Defendants, :

:

v. :

:

INVASIX, INC., :

:

Third-Party Defendant. :

Perez, J. May 29, 2026

MEMORANDUM

This dispute arises from the sale of a cosmetic medical device sold by Invasix, Inc.

(“Invasix”) to Southern Illinois Internal Medicine, Ltd. (“SIIM”). The sale was financed by De

Lage Landen Financial Services, Inc. (“DLL”) and involved several contracts entered into between

the parties. Shortly after executing the contract, SIIM had a change of heart and sought to reject

and/or return the device and made no payments it owed to DLL under the finance lease. DLL sued

SIIM for breach of contract and SIIM’s sole owner Dr. Mazhar H. Lakho for breach of personal

guaranty. SIIM and Dr. Lakho contend, however, that the contracts were the result of fraud on the

part of Invasix employee Clay Ditslear, so they brought third-party fraud-based claims against

Invasix.

Before the Court are the parties’ cross-motions for summary judgment. DLL affirmatively

moves for summary judgment on its breach of contract and breach of personal guaranty claims,

and Dr. Lakho moves for summary judgment on DLL’s breach of personal guaranty and unjust

enrichment claims. However, neither party has shown they are entitled to judgment as a matter of

law, and material factual disputes remain. Their motions must be denied. Invasix moves for

summary judgment on Defendants’ fraud-based claims. The alleged misrepresentations or

omissions upon which Defendants relied could have easily been discovered had Dr. Lakho read

the writings he signed. “[A] party may not enter into a transaction with its eyes closed to available

information and then charge that it has been deceived by another.” Cozzi Iron & Metal, Inc. v. U.S.

Office Equip., Inc., 250 F.3d 570, 574 (7th Cir. 2001) (cleaned up). For that reason and the reasons

discussed more fully below, Invasix’s motion is granted.

I. Factual Background1

Plaintiff DLL is a finance company that provides vendor financing for products and

services offered by a vendor when the vendor’s customer requires financing. DLL Statement of

Facts, ECF No. 36 ¶ 1. Third-Party Defendant Invasix is a corporation that sells aesthetic

technology, such as skin tightening treatments, laser hair removal, and resurfacing equipment,

including a device known as Morpheus8. Invasix Statement of Facts, ECF No. 40 ¶¶ 22, 23.

Defendant Dr. Mazhar H. Lakho is the sole shareholder and President of the internal medicine

practice SIIM. Id. ¶¶ 2, 11.

Invasix employed Clayton Ditslear as a Territory Manager. Id. ¶ 27. Ditslear went to SIIM’s

office several times to meet with Dr. Lakho to sell SIIM the Morpheus8. Id. ¶ 29. Ditslear collected

1 The facts in this section are undisputed unless otherwise noted. The facts are taken from the Statements of Undisputed

Facts submitted by DLL, Dr. Lakho, and Invasix, as well as the corresponding exhibits. See ECF Nos. 36 (DLL’s

SOF), 37 (Lakho SOF), and 40 (Invasix SOF), 41 (Exhibits).

Dr. Lakho’s and SIIM’s information and submitted a credit application to Financial Partners Group

(“FFP”) to determine credit worthiness and to identify potential lenders to facilitate SIIM’s

purchase of the Morpheus8. Id. ¶ 33. As part of the credit application, Dr. Lakho provided Ditslear

with his Social Security number (“SSN”). Id. ¶ 34. FFP identified DLL as a lender. Id. 40 ¶ 50.

On December 18, 2023, Ditslear met with Dr. Lakho at SIIM’s office to close on the

transaction for the Morpheus8. Id. ¶ 38. That day, Dr. Lakho executed the Customer Purchase

Agreement (“CPA”), which is the agreement of sale between SIIM and Invasix. Id. ¶ 39; see also

CPA, Ex. G, ECF No. 41-7. Dr. Lakho contends he executed the agreement based upon Ditslear’s

representation that SIIM would be able to return the Morpheus8. Id. The CPA contains no return

clause. ECF No. 41-7.

The CPA lists the price of the Morpheus8 as $121,000. Id. The CPA contains the following

relevant language:

ACCEPTANCE OF AGREEMENT By signing below, Customer is representing to

Invasix, Inc. (“Company”), which operates through the trade name InMode, that it

1) has read understands, and accepts the terms of this Customer Purchase

Agreement, the Terms and Conditions Addendum, which is available at

www.Inmodemd.com/terms-US/ and incorporated herein by reference . . . .

Customer further acknowledges that this is the complete Agreement between the

parties, is subject to the payment terms and conditions contained or referred to

herein, and expressly disclaims any additional and/or different terms and conditions

stated on any purchase orders, sales quotes or other written or oral proposals shared

or discussed between the parties.

Id. Dr. Lakho did not review the Terms and Conditions Addendum (“T&C”) on InMode’s website

before signing the Customer Purchase Agreement. ECF No. 40 ¶ 47. When asked about the clause

referring to the T&C, Dr. Lakho testified that he did not pay attention to it and that he signed

because he “trusted” Ditslear. ECF No. 41-1 at 24. Invasix and DLL agree that the T&C on

InMode’s website states in bold that “All sales and purchases under the [CPA] are final and non-

refundable. Company grants no right of return to Customer for any purchased System or other

items.” Id. ¶ 46; SIIM Dep. Tr. at 87–88, Ex. A, ECF No. 41-1 at 24. SIIM and Dr. Lakho contend

they do not have the T&C, so they are unable to confirm the accuracy of that statement. ECF No.

40 ¶ 46 and SIIM/Lakho’s Response. The T&C was not attached as an exhibit.

In addition to the CPA, Dr. Lakho signed a Lease Contract (“Lease”), which had

handwritten sections pre-populated by Ditslear, including Dr. Lakho’s SSN. Id. ¶ 52; see also

Lease, Ex. H, ECF No. 41-8; Ditslear Dep. Tr. at 87, Ex. E, ECF No. 41-5 at 24. Dr. Lakho testified

that he could not recall whether the SSN was written on the lease before he signed. See ECF No.

40 ¶ 52 and responses; Lakho Dep. Tr. at 103, Ex. A, ECF No. 41-1 at 28.

The Lease lists SIIM as the Lessee, Dr. Lakho as the Owner/Principal of SIIM, and DLL

as the Lessor. ECF No. 41-8. The Lease includes specific payment terms and a personal guaranty

provision. ECF No. 40 ¶¶ 54, 55; ECF No. 41-8. The personal guaranty specifically states:

I, the guarantor identified by the Social Security Number above, unconditionally

guaranty prompt payment of all the Lessee’s obligations. Lessor is not required to

proceed against Lessee or Equipment or enforce other remedies before proceeding

against me. I waive notice of acceptance and all other notices or demands of any

kind to which I may be entitled. I consent to any extensions or modification granted

to Lessee and the release and/or compromise of any obligations of Lessee or any

other guarantors without releasing me from my obligations. This is a continuing

guaranty and will remain in effect in the event of my death and may be enforced by

or for the benefit of any assignee or successor of Lessor. This guaranty is governed

by and construed in accordance with the Laws of the Commonwealth of

Pennsylvania and I consent to non-exclusive jurisdiction in any state or federal

court in Pennsylvania and waive trial by jury. I ACKNOWLEDGE AND AGREE

THAT IF I ENTER MY SOCIAL SECURITY NUMBER ABOVE, THEN MY

SIGNATURE, IN ADDITION TO BINDING THE LESSEE THROUGH MY

CORPORATE CAPACITY, SHALL ALSO BIND ME PERSONALLY AS A

GUARANTOR, CONFIRMING MY ACCEPTANCE OF THE OBLIGATIONS

CONTAINED IN THIS SECTION AND CONSENTING TO LESSOR

OBTAINING MY CONSUMER CREDIT REPORT IN CONNECTION WITH

THIS LEASE.

ECF No. 41-8.

A Purchase Order dated December 19, 2023, states that the Morpheus8 was sold for

$121,000 by vendor InMode to DLL and was shipped to SIIM, the Lessee. Purchase Order, Ex. S,

ECF No. 41-19.

At some point after executing the CPA and Lease, SIIM determined it did not want the

Morpheus8. ECF No. 40 ¶ 80. On an unknown date between December 18, 2023, and January 2,

2024, the Morpheus8 was delivered to SIIM. ECF No. 40 ¶ 76. Dr. Lakho was out of the office

that day. Id. SIIM contends it immediately rejected the equipment. Id. ¶ 76 and SIIM/Lakho’s

Response. Invasix contends the equipment was signed for by a SIIM employee, but there is no

evidence in the record establishing that assertion. See id. ¶ 78 (citing ECF No. 41-1 at 32 (Lakho

testifying that he did not know who was in the office on the day the Morpheus8 was delivered, but

he thinks the manager Tammy was present and “[s]he may have been” the person who signed for

it)). Defendants contend the issue of rejection remains in dispute. Id. ¶ 78 and SIIM/Lakho’s

Response.

On the morning of January 2, 2024, Ditslear went to SIIM’s office to unbox the Morpheus8

and make sure everything was “firing properly.” Id. ¶ 77. Dr. Lakho was not present at that time.

Id. ¶ 77 and SIIM/Lakho’s Response. It is not clear exactly what time Ditslear arrived, other than

that he testified it was “first thing in the morning.” See ECF No. 41-5 at 28. At 9:59 a.m. on January

2, 2024, Dr. Lakho texted Ditslear asking him not to unbox the Morpheus8 and stating, “[w]e may

not be able to buy the machine in anyway.” Ex. K, ECF No. 41-11 at 6. Ditslear did not see the

text message until after he unboxed the machine. ECF No. 41-5 at 28. At 11:36 a.m., Ditslear

responded saying, “the Morpheus is unboxed in your office.” Id. Ditslear testified that if he had

seen Dr. Lakho’s text message before unboxing the Morpheus8, he would not have unboxed it.

ECF No. 41-5 at 28. SIIM requested to return the Morpheus8 device to Invasix after it was

delivered. ECF No. 37 ¶ 13. Neither DLL nor Invasix has picked up the device. Id. ¶ 14. Ditslear

eventually stopped responding to Dr. Lakho’s requests to return it. See ECF No. 41-5 at 32. Dr.

Lakho and SIIM contend the Morpheus8 remains in the packaging and has never been plugged in,

turned on, or used. ECF No. 40 ¶¶ 90–93. SIIM has never made any payment to DLL pursuant to

the Lease. Id. ¶ 83.

II. Procedural History

On February 20, 2025, DLL sued Defendants SIIM and Dr. Lakho in the Court of Common

Pleas of Chester County Pennsylvania, for breach of the Lease, breach of personal guaranty, and

unjust enrichment. ECF No. 1-1. On March 27, 2024, Defendants removed the case to this Court,

asserting diversity jurisdiction. ECF No. 1. On April 3, 2025, Defendants answered the Complaint,

asserting a number of affirmative defenses. ECF No. 9.

On June 24, 2025, Defendants filed a Third-Party Complaint against InMode, Ltd.

(“InMode”) and Invasix Inc. (“Invasix” or “Third-Party Defendant”), raising three claims:

Violation of the Illinois Consumer Fraud and Deceptive Business Practices Act (“Consumer Fraud

Act” or “ICFA”), fraudulent inducement, and fraudulent misrepresentation. ECF No. 13. On July

30, 2025, Defendants voluntarily dismissed their claims against InMode without prejudice. ECF

No. 17. Invasix answered the Third-Party Complaint on August 8, 2025, raising eighteen

affirmative defenses. ECF No. 19.

On October 27, 2025, DLL and Invasix filed motions for a non-jury trial. ECF Nos. 25 &

26. Defendants opposed only with respect to their claims against Invasix. ECF No. On November

20, 2025, the Court granted in part the motions, holding DLL’s claims against Defendants must be

heard in a bench trial, and Defendants’ claims against Invasix must be heard by a jury. ECF No.

30.

On April 7, 2026, each party moved for summary judgment. ECF Nos. 35 (De Lage MSJ),

38 (Lakho MSJ), 39 (Invasix MSJ). Oppositions and replies have been filed, and the motions are

ripe for review.

III. Summary Judgment Standard

Summary judgment is properly granted when “there is no genuine dispute as to any

material fact and the movant is entitled to judgment as a matter of law.” Fed. R. Civ. P. 56(a). Facts

are material if they “might affect the outcome of the suit under the governing law.” Physicians

Healthsource, Inc. v. Cephalon, Inc., 954 F.3d 615, 618 (3d Cir. 2020). A dispute as to those facts

“is genuine if the ‘evidence is such that a reasonable jury could return a verdict for the nonmoving

party.’” Id. (quoting Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248 (1986)). A party asserting

a fact is genuinely disputed must support its contention by citing to particular materials in the

record. Fed. R. Civ. P. 56(c).

A party pursuing claims of fraud must prove them by clear and convincing evidence, and

at summary judgment, the Court must evaluate the evidence “through the prism of the substantive

evidentiary burden.” Richelieu Foods, Inc. v. New Horizon Warehouse Distrib. Ctr., 67 F. Supp. 3d

903, 915 (N.D. Ill. 2014) (quoting Anderson, 477 U.S. at 254; and citing JP Morgan Chase Bank,

N.A. v. Asia Pulp & Paper Co., 707 F.3d 853, 864 (7th Cir. 2013)).

IV. DLL Is Not Entitled to Summary Judgment on its Breach of Contract Claim

Against SIIM.

A. The Lease is a Finance Lease Governed by 13 Pa. C.S.A. § 2A103 (Article

2A of the UCC).

As an initial matter, the parties dispute whether the Lease is a finance lease under Article

2A of the UCC or a loan. See ECF No. 45 at 9–10. If it is a finance lease, the parties agree that

SIIM’s obligation to pay became irrevocable and independent upon acceptance of the Morpheus8.

13 Pa. C.S.A. § 2A407; see also ECF No. 45 at 10. The Court finds that the Lease is a finance

lease under Article 2A.

“A finance lease is the product of a three party transaction,” in which a “supplier

manufactures or supplies the goods pursuant to the lessee’s specification,” and the lessor and lessee

“enter into a lease or sublease of the goods.” 13 Pa. C.S.A. § 2A103, cmt (g). “Due to the limited

function usually performed by the lessor, the lessee looks almost entirely to the supplier for

representations, covenants and warranties.” Id. “Even ‘if a transaction does not qualify as a finance

lease, the parties may achieve the same result by agreement.’” De Lage Landen Fin. Servs., Inc. v.

Rasa Floors, LP, 792 F. Supp. 2d 812, 828 (E.D. Pa. 2011) (brackets omitted) (quoting 13 Pa.

C.S.A. § 2A103, cmt. (g)); see also De Lage Landen Fin. Servs., Inc. v. M.B. Mgmt. Co., Inc., 888

A.2d 895, 900–01 (Pa. Super. Ct. 2005) (finding the parties bound by the language contained in

the contract explicitly agreeing that the lease was a finance lease as defined in article 2A). When

parties form a finance lease under Article 2A, the lessee’s obligations “become irrevocable and

independent upon the lessee’s acceptance of the goods.” 13 Pa. C.S.A. § 2A407. This is known as

a “hell or high water” clause. Id., cmt. 1; see also Rasa Floors, 792 F. Supp. 2d at 828.

Here, Section 10 of the Lease states that it is a “Finance Lease” under Article 2A and that

SIIM “irrevocably waive[s] any and all rights and remedies . . . under UCC sections 2A-508

through 2A-522.” ECF No. 41-8. Section 1 mirrors Article 2A’s “hell or high water” clause, stating:

“You agree that this [sic] your obligations under this Lease are absolute, unconditional, and not

subject to cancellation, reduction, setoff or counterclaim.” Id. Section 4 directs the lessee to make

any claims relating to maintenance, service, and supplies against the service provider, not DLL,

and requires the lessee to continue paying DLL, whether or not requested services are provided.

Id. Taken together, the Lease’s terms clearly establish it is a finance lease, regardless of whether it

meets the statutory requirements. See M.B. Mgmt., 888 A.2d at 900–01.

Defendants attempt to muddy the waters by pointing to the testimony of DLL’s Rule

30(b)(6) designee Andrew Chesbro, wherein he characterized the transaction as a loan. See ECF

No. 45 at 9 (quoting Chesbro Dep., ECF No. 41-6 at 15). This testimony does not change the terms

of the Lease. A lay witness’s testimony as to his understanding of the parties’ agreement does not

create a dispute of material fact where the contract’s terms are unambiguous. “Contract

interpretation is a question of law that requires the court to ascertain and give effect to the intent

of the contracting parties as embodied in the written agreement. . . . When a writing is clear and

unequivocal, its meaning must be determined by its contents alone.” In re Old Summit Mfg., LLC,

523 F.3d 134, 137 (3d Cir. 2008) (quoting Dep’t of Transp. v. Pa. Indus. for the Blind &

Handicapped, 886 A.2d 706, 711 (Pa. Commw. Ct. 2005)). Here, the Lease is clear and

unequivocal that it is a finance lease governed by Article 2A of the UCC. The Court must determine

its meaning by the contents of the Lease alone. Chesbro’s characterization of the transaction does

not overcome the written terms of the Lease.

B. There is a Genuine Dispute as to Whether SIIM Accepted or Rejected the

Morpheus8.

Even though the Lease is a finance lease with a “hell or high water” clause, that provision

cannot take effect if the Morpheus8 was never accepted. DLL argues the delivery of the

Morpheus8, for which a SIIM staff member signed, constituted acceptance. ECF No. 35-1 at 12.

Defendants contend the Morpheus8 was not accepted, and that Dr. Lakho attempted to reject the

device by texting Ditslear not to unbox it and later seeking to return it. See ECF No. 45 at 14.2 The

2 Section 3 of the Lease provides: “You acknowledge that by signing below you have tested and accepted the

Equipment and that it is in good working order.” ECF No. 41-8. Defendants contend there is no “signature below,” so

the signing of the Lease itself cannot constitute acceptance. ECF No. 45 at 14. The Court does not resolve this issue

Court cannot resolve this factual dispute on the current record, so summary judgment is not

appropriate.

Under Article 2 of the UCC, “[a]cceptance of goods occurs when the buyer . . . fails to

make an effective rejection” after having “a reasonable opportunity to inspect them.” 13 Pa. C.S.A.

§ 2606(a). A rejection of goods “must be within a reasonable time after their delivery.” 13 Pa.

C.S.A. § 2602(a). There is no requirement that rejection occur before or at the time of delivery. Id.

Even a wrongful rejection may still be effective if it is timely. Integrated Circuits Unltd. v. E.F.

Johnson Co., 875 F.2d 1040, 1042 (2d Cir. 1989) (quoting 1 White & Summers, Uniform

Commercial Code 314 (2d ed. 1980)).3

DLL relies on the Lease’s “hell or high water” clause, which states the Lessee’s obligations

are “absolute, unconditional, and are not subject to cancellation, reduction, setoff or counterclaim.”

DLL SOF ¶ 18, ECF No. 36; see also ECF No. 45 at 5. However, that puts the cart before the

horse. The clause only takes effect upon acceptance of the goods. See 13 Pa. C.S.A. § 2A407 (“In

the case of a finance lease . . . , the lessee’s promises under the lease contract become irrevocable

and independent upon the lessee’s acceptance of the goods.” (emphasis added)).

DLL asserts that Dr. Lakho’s staff accepted delivery of the Morpheus8 and that Dr. Lakho

“took no steps whatsoever to prevent acceptance.” ECF No. 35-1. DLL cites no law supporting its

contention that acceptance occurred at the time of delivery. It is undisputed that Dr. Lakho was not

present when the device was delivered. Defendants contend they tried to reject the Morpheus8

after its delivery on multiple occasions and that SIIM never used, plugged in, or turned on the

at this stage because DLL does not address this argument, nor does it appear to rely on Section 3 to establish

acceptance. However, the Court acknowledges that DLL’s 30(b)(6) witness testified that DLL anticipated it would

seek a signature after the equipment had been received, tested, and accepted by SIIM. ECF No. 41-6 at 16–17.

3 Although DLL would be entitled to damages for breach due to a wrongful rejection, those damages would be limited

to actual damages, not the contract price. Id.

device. ECF No. 40 at 51–53. Absent more arguments related to acceptance and rejection,

supported by citations to legal authority and the record, the Court cannot determine the Morpheus8

was accepted. Summary judgment is therefore denied on DLL’s breach of contract claim against

SIIM.4

V. Neither DLL Nor Dr. Lakho Are Entitled to Summary Judgment on DLL’s

Breach of Personal Guaranty Claim against Dr. Lakho.

As discussed above, the Court cannot conclude the Morpheus8 was accepted, thereby

triggering SIIM’s unconditional obligations under the Lease. Dr. Lakho cannot be personally

bound to guarantee SIIM’s obligations if SIIM had no such obligations in the first place.

Accordingly, DLL’s motion for summary judgment on the breach of guaranty claim must be

denied.

Dr. Lakho has also not established he is entitled to judgment as a matter of law on the

breach of personal guaranty claim. Dr. Lakho’s arguments focus on two primary issues: first, he

argues that the personal guaranty clause contained a condition precedent requiring him to

personally enter his SSN on the Lease and raises a factual dispute as to whether Ditslear wrote the

SSN on the Lease before or after Dr. Lakho signed; second, Dr. Lakho argues there was no express,

unambiguous evidence that he intended to bind himself personally.

A. Ditslear Wrote Dr. Lakho’s SSN on the Lease Before Signing.

The Court first resolves Dr. Lakho’s attempt to create a factual dispute as to whether

Ditslear wrote his SSN on the Lease before or after signing. It is undisputed that Ditslear wrote the

SSN, not Dr. Lakho. It is further undisputed that Ditslear did so before presenting the Lease to Dr.

Lakho for signing.

4 DLL also argues that Defendants’ fraud claims against Invasix fail. The Court need not engage with DLL’s arguments

relating to fraud because it addresses Defendants’ fraud claims against Invasix in connection with Invasix’s motion.

Ditslear testified unequivocally that “everything was prepopulated besides [Dr. Lakho’s

signature and tax ID.]” ECF No. 41-5 at 24. He further confirmed that he handwrote the SSN

before he arrived at Dr. Lakho’s office. Id. Dr. Lakho did not create a genuine dispute in his

deposition testimony (or elsewhere). He testified only that he did not recall whether his SSN

appeared on the Lease when he signed. ECF No. 41-1 at 28. Dr. Lakho’s inability to recall whether

his SSN was written on the document before he signed it does not amount to a genuine dispute that

it was there. See Bradshaw v. N.J., No. 18-14089, 2026 WL 310110, at *14 (D.N.J. Feb. 5, 2026)

(plaintiff’s “inability to recall a discussion . . . does not genuinely dispute that such a discussion

occurred”).5

B. The Court Cannot Determine as a Matter of Law at this Stage that Dr.

Lakho Intended to be Bound by the Personal Guaranty.

Given there is no dispute of material fact as to whether the SSN appeared on the Lease

when Dr. Lakho signed it, the Court must decide whether the Lease required Dr. Lakho to

personally enter his SSN to trigger the personal guaranty and if so, whether Dr. Lakho ratified the

Lease by signing with his SSN pre-populated. The Court answers the first question affirmatively

but finds there is a factual dispute as to Dr. Lakho’s ratification.

“[G]uaranty contracts [are] subject to [the] same rules of interpretation as other

agreements.” Garden State Tanning, Inc. v. Mitchell Mfg. Group Inc., 273 F.3d 332, 335 (3d Cir.

2001) (citing Mtg. House Lane, Ltd. v. Melso, 682 A.2d 854, 857 (Pa. Super. Ct. 1993)). “The

fundamental rule in interpreting the meaning of a contract is to ascertain and give effect to the

intent of the parties.” Binswanger of Pa., Inc. v. TSG Real Estate LLC, 217 A.3d 256, 262 (Pa.

5 Dr. Lakho points to evidence in the record that Ditslear received Dr. Lakho’s email address four days after the Lease

was signed and the email address appears on the Lease. See ECF No. 41-1 at 28; ECF No. 41-5 at 31. He argues this

is evidence that the email address and SSN were added after signing. However, this speculation does not negate that

Ditslear testified he had collected the email address four days earlier on all of the documents and that the SSN was

pre-populated. ECF No. 41-5 at 24, 31.

2019). It is well settled that the parties’ intent must be determined by the writing itself, and when

the writing is clear and unambiguous, the court must determine the writing’s meaning only by its

terms. Id. Additionally, the court must “endeavor to find an interpretation which will effectuate the

reasonable result intended” before interpreting a provision “in such a way as to lead to an absurdity

or make the . . . contract ineffective to accomplish its purpose.” Id. (citation omitted). However,

where the contract is ambiguous, Pennsylvania courts construe the ambiguities against the drafter.

Franklin Interiors v. Wall of Fame Mgmt. Co., Inc., 511 A.2d 761, 763 (Pa. 1986). Nonetheless, a

signer’s “unilateral error” with respect to the contract’s interpretation or legal effect does not create

an ambiguity, nor does it “afford[] . . . more grounds for relief than does ignorance of the words.”

Denlinger, Inc. v. Dendler, 608 A.2d 1061, 1070 (Pa. Super. Ct. 1992) (quoting Schoble v. Schoble,

37 A.2d 604, 605 (Pa. 1944)).

Paragraph 11 of the Lease contains contradictory sentences: “Personal Guaranty: I, the

guarantor identified by the Social Security Number above, unconditionally guaranty prompt

payment of all the Lessee’s obligations. . . . I ACKNOWLEDGE AND AGREE THAT IF I ENTER

MY SOCIAL SECURITY NUMBER ABOVE, THEN MY SIGNATURE, . . . SHALL ALSO

BIND ME PERSONALLY AS A GUARANTOR . . . .” ECF No. 41-8. The first sentence indicates

the SSN is merely an identifier and does not require personal entry onto the form, while the final

all-caps sentence appears to require the signer to personally enter the SSN for the personal guaranty

to take effect. Each party relies on the portion of the clause that is favorable to it, and neither party

attempts to reconcile the two.

Dr. Lakho characterizes the final sentence as containing a condition precedent to the

enforceability of the personal guaranty. Pennsylvania law disfavors conditions precedent and will

only construe clauses as such where that “clearly appears to have been the parties’ intention.” Acme

Markets, Inc. v. Fed. Armored Exp., Inc., 648 A.2d 1218, 1220 (Pa. Super. Ct. 1994). However,

offers must be accepted “in the mode and manner expressly provided by the terms of the offer.”

Franklin Interiors, 511 A.2d at 762. “[T]he offeror is the master of his offer,” Restatement

(Second) Contracts § 58 cmt. a, and “a written instrument must be strictly construed against its

maker.” InfoComp, Inc. v. Electra Prods., Inc., 109 F.3d 902, 906 (3d Cir. 1997) (quoting Cucci v.

Rollins Protective Servs. Co., 546 A.2d 1131, 1135 (Pa. Super. Ct. 1988)). The drafter’s failure to

follow its own conditions of acceptance precludes it from relying on the clause for which the

conditions were not met. Id.

In Franklin Interiors, the formation of a valid contract was expressly conditioned upon the

written approval by an officer of Franklin Interiors. 511 A.2d at 763. The fact that no officer entered

a signature on the document was a facial defect that precluded formation. Id. Pennsylvania courts

have consistently applied this principle to agreements requiring specific signatures or approval.

See InfoComp, Inc., 109 F.3d at 905–06. Although, here there is a question of entry of an SSN and

not a signature, the Court finds that the Lease’s contradictory, ambiguous clause must be construed

against the drafter, DLL. Accordingly, absent ratification, Dr. Lakho cannot be bound by a personal

guaranty when DLL failed to follow its own conditions of acceptance.

There is, however, a dispute as to whether Dr. Lakho’s signature constituted ratification of

the agreement. DLL argues that even if the personal guaranty clause required Dr. Lakho to

personally enter his SSN, he ratified it by signing the Lease with the pre-written SSN. Dr. Lakho

does not directly respond to this argument, but DLL has not established it is entitled to judgment

as a matter of law on this issue. See Fed. R. Civ. P. 56(e)(3). “An agreement can be ratified by a

party through his actions when he shows an acceptance or adoption of the agreement with an intent

to ratify and knowledge of the material consequences.” Bayview Loan Serv., LLC v. Etreih, No.

130801821, 2016 WL 723071, at *3 (Phila. Ct. Com. Pl. Jan. 20, 2016), aff’d 2016 WL 6441300

(Pa. Super. Ct. Nov. 1, 2026). The Court agrees with Defendants that Dr. Lakho’s signature could

constitute ratification; however, the argument has not been fully briefed. Summary judgment is,

therefore, denied.

VI. Dr. Lakho Is Not Entitled to Summary Judgment on DLL’s Unjust Enrichment

Claim.

Under Pennsylvania law, a plaintiff raising an unjust enrichment claim must prove: (1) a

benefit conferred on defendant by plaintiff; (2) defendant’s appreciation of the benefit; and (3)

“acceptance and retention of such benefits under such circumstances that it would be inequitable

for defendant to retain the benefit without payment of value.” Schenck v. K.E. David, Ltd., 666

A.2d 327, 328 (Pa. Super. Ct. 1995).

A. Dr. Lakho May Be Held Personally Liable under the Participation

Theory

Dr. Lakho’s argument that he cannot be personally liable for unjust enrichment as a

corporate officer fails because he personally participated in the alleged misfeasance. Generally, an

officer of a corporation cannot be liable for a tort committed by the corporation unless he

personally takes part in the tort. Wicks v. Milzoco Builders, Inc., 470 A.2d 86, 90 (Pa. 1983). This

is called “the participation theory.” Id.; see also Animalscan, LLC v. Live Oak Veterinary

Specialists, LLC, No. 18-2288, 2019 WL 3801559, at *5 (M.D. Pa. Aug. 13, 2019). “Participation

theory, in simple terms, is a theory which imposes personal liability on corporate officers or

shareholders where they have personally taken part in the actions of the corporation.” First

Realvest, Inc. v. Avery Builders, Inc., 600 A.2d 601, 603 (Pa. Super. Ct. 1991) (citing Wicks, 570

A.2d at 89–90). The participation theory is only applicable where the claims involve misfeasance

by the actor (“the improper performance of an act”); nonfeasance (“the omission of an act which

a person ought not to do”) is not enough. Animalscan, 2019 WL 3801559 at *5 (quoting Aetna,

Inc. v. Health Diagnostic Lab’y, Inc., No. 15-1868, 2015 WL 9460072, at *9 (E.D. Pa. Dec. 28,

2015).

Aetna compared two Pennsylvania cases applying the participation theory. First, Aetna

explained that a corporate officer who personally supervises the refinancing of a mortgage can be

held liable for the mortgagors’ loss suffered as a result of the officer’s negligence. 2015 WL

9460072 at *9 (discussing Loeffler v. McShane, 539 A.2d 876 (Pa. Super. Ct. 1988)). By contrast,

a corporate president cannot be held liable for wrongful death as a result of a negligently

maintained helicopter where the president did not personally complete the maintenance. Id.

(discussing Shay v. Flight C Helicopter Servs., 822 A.2d 1 (Pa. Super. Ct. 2003)). The president’s

nonfeasance—failing to supervise the maintenance—was insufficient to invoke the participation

theory. Id. Applying these principles at the pleading stage, Aetna found that allegations of

personally planning, authorizing, and directing a fraud, including submitting bills with false and

fraudulent charges and personally profiting from the fraud due to part ownership in the company,

were sufficient to invoke the participation theory. Id.

Here, it is clear that Dr. Lakho was the only individual involved in entering the transaction

between SIIM and DLL. Dr. Lakho is the sole owner of SIIM and was the sole decisionmaker

throughout this process. The participation theory would apply, assuming all other elements of the

unjust enrichment claim are met. Dr. Lakho is not entitled to summary judgment on those grounds.

B. It Is Disputed Whether Defendants Voluntarily Retained the Morpheus8

and Whether Such Retention Is Unjust.

Dr. Lakho also argues DLL’s unjust enrichment claim fails because SIIM and Dr. Lakho

never used the Morpheus8 and, therefore, they received no benefit. ECF No. 38-1 at 5. The Court

is not convinced that Defendants’ decision not to unwrap or use the Morpheus8 means that no

benefit was received. However, the dispute as to the acceptance and rejection of the Morpheus8

bears on DLL’s unjust enrichment claim, making summary judgment again inappropriate.

The Restatement (Third) of Restitution and Unjust Enrichment, § 1 cmt. d, explains that

the benefit that supports a claim for restitution may take any form: e.g., services, property, saved

expenditures. The Restatement further explains that a defendant can be liable in restitution for

benefits it attempted to refuse but nonetheless received. Id. cmt. e (describing elements of unjust

enrichment claims as unhelpful, in particular “the defendant’s ‘appreciation or knowledge of the

benefit,’ is both mysterious and potentially mischievous. If the requirement is taken to mean that

a defendant cannot be liable in restitution for benefits of which the defendant was unaware—or

for benefits that the defendant attempted to refuse—it is plainly incorrect.”)). This is consistent

with Pennsylvania law, which focuses most significantly on whether the retention of the benefit is

unjust and which allows for recovery where the benefit was “either wrongfully secured or

passively received.” EBC, Inc. v. Clark Bldg. Sys., 618 F.3d 253, 273 (3d Cir. 2010) (cleaned up);

see also Water Polo I, L.P. v. W. Hanover Twp. Sewer Auth., 301 A.3d 1009, 1019 (Pa. 2023).

Here, the questions of whether Defendants “wrongfully secured or passively received” the

Morpheus8—or whether their efforts at rejection negate that they passively received the device—

and whether that is unjust should be decided by a fact finder. Summary judgment is, therefore,

denied.

VII. Invasix Is Entitled to Summary Judgment.

Defendants raised three causes of action against Invasix: Violation of the Consumer Fraud

Act (“ICFA”) (First Count), Fraudulent Inducement (Second Count), and Fraudulent

Misrepresentation (Third Count). ECF No. 13.6 Invasix moves for summary judgment on all

claims. The Court grants Invasix’s motion because the misrepresentations and omissions

Defendants identify cannot support their fraud claims under Illinois law.

Illinois common law fraud claims require a showing of: “(i) a false representation of

material fact, (ii) made with knowledge or belief of that representation’s falsity, (iii) made with the

purpose of inducing another party to act or to refrain from acting, and (iv) the other party

reasonably relies upon the representation to its detriment.” Colagrossi v. Royal Bank of Scotland,

57 N.E.3d 601, 611 (Ill. App. Ct. 2016) (citation omitted) (fraudulent inducement); see also Doe

v. Dilling, 888 N.E.2d 24, 35–36 (Ill. 2008) (fraudulent misrepresentation). “Fraud in the

inducement exists where the party fully understands what he is signing and is aware of the nature

and character of the instrument he has executed, but is deceived by fraudulent representations as

to the facts outside the instrument itself.” Colagrossi, 57 N.E.3d at 611.

To prevail on a consumer fraud claim under the ICFA, a plaintiff must prove: “(1) a

deceptive act or practice by the defendant, (2) the defendant’s intent that the plaintiff rely on the

deception, (3) the occurrence of the deception in a course of conduct involving trade or commerce,

and (4) actual damage to the plaintiff that is (5) a result of the deception.” Ambrosius v. Chicago

Athletic Clubs, LLC, 203 N.E.3d 239, 249 (Ill. App. Ct. 2021) (quoting De Bouse v. Bayer AG, 922

N.E.2d 309, 313 (Ill. 2009)). Deceptive acts include “the use or employment of any deception,

fraud, false pretense, false promise, misrepresentation or the concealment, suppression or omission

of any material fact, with intent that others rely upon the concealment, suppression or omission of

such material fact . . . in the conduct of any trade or commerce.” Id. (quoting 815 ILCS 505/2).

6 The parties agree that Illinois law applies to these claims. See ECF No. 39-1 at 11–12 (discussing standards under

Illinois law); ECF No. 46 at 10 (arguing Illinois law applies and explaining that “[t]his point matters because Illinois

law permits fraud-in-the-inducement claims to proceed notwithstanding an integration clause . . . .”).

Courts “must consider whether the act was deceptive as reasonably understood in light of all the

information available to plaintiffs.” Phillips v. DePaul Univ., 19 N.E.3d 1019, 1031 (Ill. App. Ct.

2014).

Defendants’ fraud theory is based on three purported misrepresentations: (1) Ditslear

promised to add a term to the CPA that would allow SIIM to return the Morpheus8 but did not; (2)

Ditslear failed to disclose the personal guaranty contained in the Lease; and (3) Dr. Lin, a doctor

to whom Invasix directed Dr. Lakho for discussion of the Morpheus8, received a $2,500

commission on the sale. The Court takes each in turn.

A. The Promise to Add a Return Clause Cannot Support Defendants’ Fraud-

Based Claims.

Whether Ditslear falsely represented that he would write in a provision that would allow

Defendants to return the Morpheus8 is a disputed fact. It is undisputed that Dr. Lakho asked for

such a term to be included. However, Ditslear contends he told Dr. Lakho that could not be

accommodated, while Dr. Lakho contends he promised that he would add the term. Ditslear Dep.,

ECF No. 41-5 at 17; Lakho Dep., ECF No. 41-1 at 25, 40. The Court must construe this factual

dispute in the nonmovant’s favor and infer that the promise was made and then not fulfilled. The

question then becomes whether that fact may be actionable under Illinois law. It is not.

For their common law fraud claims, Defendants cannot rely on Ditslear’s misrepresentation

that he would add a return clause because a party cannot justifiably rely on an oral promise not

contained within a contract that the party had the opportunity to review. “[T]he defense of fraud

is, in most situations, unavailable to avoid the effect of the written agreement where the

complaining party could have discovered the fraud by reading the instrument, and was in fact

afforded a full opportunity to do so.” Colagrossi, 57 N.E.3d at 611 (quoting Belleville Nat’l Bank

v. Rose, 456 N.E.2d 281, 284 (Ill. App. Ct. 1983)) (affirming grant of summary judgment where

contract included integration clause and plaintiff “had ample opportunity to consider the terms set

forth in the” fully integrated employment agreement). “[A] party may not enter into a transaction

with its eyes closed to available information and then charge that it has been deceived by another.”

Cozzi Iron & Metal, 250 F.3d at 574 (cleaned up). In other words,

One is under a duty to learn, or know, the contents of a written contract before he

signs it, and is under a duty to determine the obligations which he undertakes by

the execution of a written agreement. . . . And the law is that a party who signs an

instrument relying upon representations as to its contents when he has had an

opportunity to ascertain the truth by reading the instrument and has not availed

himself of the opportunity, cannot be heard to say that he was deceived by

misrepresentations.

Belleville Nat’l Bank, 456 N.E.2d at 284 (citation omitted).

Dr. Lakho did not read the CPA and instead relied on Ditslear’s assurance that “everything

was okay,” which Dr. Lakho interpreted to mean he had added the return clause. See ECF No. 41-

1 at 26–27. However, Dr. Lakho was not forced to sign the agreement without reading it, nor did

he sign it under any duress. Id. at 25–26. He was afforded the opportunity to read the CPA and

chose not to. Moreover, the CPA contains an integration clause:

Customer [SIIM] further acknowledges that this is the complete Agreement

between the parties, is subject to the payment terms and conditions contained or

referred to herein, and expressly disclaims additional and/or different terms and

conditions stated on any purchase orders, sales quotes or other written or oral

proposals shared or discussed between the parties.

ECF No. 41-7. The integration and nonreliance clause is determinative. See Colagrossi, 57 N.E.3d

at 612. Illinois law does not allow Defendants to claim to have been deceived by

misrepresentations that could have discovered by reading the CPA. See id.

Likewise, Defendants cannot establish they were actually deceived by the purported

misrepresentation as required by the ICFA. The ICFA does not require a showing of justifiable

reliance; however, it does require proof that Defendants were “actually deceived by the

misrepresentation in order to establish the element of proximate causation.” Avery v. State Farm

Mut. Automobile Ins. Co., 835 N.E.2d 801, 861 (Ill. 2005) Whether an act was deceptive must be

considered “in light of all the information available to plaintiffs.” Phillips, 19 N.E.3d at 1031.

In Phillips, the Appellate Court of Illinois affirmed the dismissal of a complaint against a

university alleging it had misrepresented employment and salary history of recent law school

graduates. Id. at 1024. The plaintiffs contended the information was “incomplete, false and

materially misleading” because the employment data included jobs that did not require a J.D. and

because the salary data was based only on full-time employment. Id. at 1024–25. The Court

considered all the information available to the plaintiffs, including that the plaintiffs had more

information than what the university reported on the website. Id. at 1031. For example, the ABA

Guides, which the plaintiffs were aware of, provided additional information stating that members

of each graduating class obtained “legal, nonlegal, and full-and part-time jobs,” as well as

expressly stating that some of the reported jobs did not require legal training. Id. Because the

plaintiffs had information available to them that would have negated any misrepresentation, the

court concluded the plaintiffs failed to adequately plead the university committed a deceptive act

or practice by misrepresenting the employment information. Id.

Similarly here, when examining all the information available to Defendants, they have not

shown that Invasix or Ditslear committed a deceptive act by misrepresenting a return clause would

be included. It clearly was not. The CPA, a one-page document containing an integration clause

and no return clause, had no provision allowing for return of the device. Dr. Lakho could have read

the CPA before signing but did not. Although Defendants need not prove justifiable reliance for an

ICFA claim, they cannot assert a deceptive act occurred when Dr. Lakho had the information at his

fingertips to ascertain the truth.

B. The Failure to Disclose the Guaranty Clause Cannot Support Defendants’

Fraud-Based Claims.

For the same reasons, Defendants cannot maintain common law or statutory fraud-based

claims based on Ditslear’s failure to tell Dr. Lakho that signing the Lease with his SSN on it would

bind him personally for the full amount of the obligation. Again, this language appeared on the

Lease, which Dr. Lakho claimed he did not read. ECF No. 41-1 at 30. That Dr. Lakho neglected to

read the Lease does not mean Ditslear concealed any material facts. In fact, nothing was concealed

because the clause was presented to Dr. Lakho in black and white. Defendants cannot assert they

were deceived when the clause was written into the agreement Dr. Lakho signed.

C. The Failure to Disclose the Referral Fee Cannot Support Defendants’

Fraud-Based Claims.

Defendants present a third alleged misrepresentation in their opposition to Invasix’s

motion: Invasix failed to disclose a commission paid to Dr. Lin, a doctor with whom Dr. Lakho

spoke about the benefits of the Morpheus8. Before signing the CPA, Dr. Lakho had wanted to

speak with a doctor who used the Morpheus8. ECF No. 41-1 at 23–24. Ditslear connected Dr.

Lakho with Dr. Lin, a Pennsylvania physician whom Invasix uses as a “key opinion leader.”

Ditslear Dep., ECF No. 41-5 at 19. Dr. Lin “spoke highly about the machine” and the revenue it

generated. Lakho Dep., ECF No. 41-1 at 23–24; ECF No. 41-5 at 19. Dr. Lakho asked Ditslear for

additional doctors who used the machine, and Ditslear provided a link to a website with a list of

doctors, which Dr. Lakho did not visit. ECF No. 41-1 at 24. Ditslear testified that Dr. Lin received

a $2,500 commission from Invasix that was contingent on the sale closing, but he did not know

whether Dr. Lin disclosed this financial interest to Dr. Lakho. ECF No. 41-5 at 19. Dr. Lakho was

not asked about the referral fee or commission at his deposition. The referral fee could not have

been discovered by reading the CPA.

Nonetheless, Defendants cannot rest on this misrepresentation because they have not

established it was material or that it caused them harm. Defendants do not contend that Dr. Lin

misrepresented anything about the Morpheus8 because he would benefit from the sale. Absent

some misrepresentation by Dr. Lin due to his potential bias, there can be no harm resulting from

Dr. Lakho’s belief that Dr. Lin was impartial. See Ambrosius, 203 N.E.3d at 249 (actual damage

must result from material misrepresentation or omission for ICFA claim); Colagrossi, 57 N.E.3d

at 611 (reasonable reliance must be to party’s detriment for common law fraud claim).

Additionally, the harm Defendants raise relates to the contract itself, not how the machine

functioned or the amount of revenue they earned from its use—the topics about which Dr. Lin

spoke. Defendants have, therefore, not put forth sufficient evidence in support of their fraud claims

against Invasix, and Invasix’s motion for summary judgment is granted.

VIII. Conclusion

For the foregoing reasons, the Court grants Invasix’s motion for summary judgment and

denies DLL’s and Dr. Lakho’s motions for summary judgment.

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.